Overview
Straight Talk with the Expert Surrounding COVID-19 and Your Patients with ILD
ILD & COVID-19: What Have We Learned?
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
Dr. Imre Noth summarizes what we have learned about COVID-19 and its implications for patients with interstitial lung disease (ILD) while sharing his own front-line clinical experience managing patients admit the pandemic. Talking points include mitigating risks of COVID-19 in patients with ILD, strategies to help patients continue ILD treatment and supportive care, as well as strategies to differentiate post-ARDS fibrosis and ILDs.
This activity is intended for primary care providers, pulmonologists, respiratory therapists, nurse practitioners, and physician assistants who treat patients with ILD.
Proper knowledge about COVID-19 risk mitigation, identification, and management is critical, particularly in high-risk patients, such as those with ILD. The purpose of the activity is to review the latest evidence surrounding COVID-19 and discuss the pandemic’s implications for managing patients with ILD. Upon completion of this activity, clinicians will be better able to advise their patients with ILD on recommended practices to mitigate risks from COVID-19 complications and will be better aware of COVID-19-related practice changes that will impact their patients with ILD.
Upon completion of this activity, participants will be able to:
• Introduce patient communication strategies to mitigate risks from COVID-19 complications
• Identify COVID-19 risk mitigation strategies for ILD patients, including optimal telemedicine practices
• Review emerging clinical data that may inform the differential diagnosis of ILD and COVID-19
• Introduce patient communication strategies to mitigate risks from COVID-19 complications
• Identify COVID-19 risk mitigation strategies for ILD patients, including optimal telemedicine practices
• Review emerging clinical data that may inform the differential diagnosis of ILD and COVID-19
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by educational grants from Boehringer Ingelheim Pharmaceuticals and Genentech, Inc.
Imre Noth, MD
Chief of Pulmonary & Critical Care Medicine
Professor of Medicine
University of Virginia School of Medicine
Charlottesville, Virginia
Chief of Pulmonary & Critical Care Medicine
Professor of Medicine
University of Virginia School of Medicine
Charlottesville, Virginia
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Imre Noth, MD
Consulting Agreements: Boehringer Ingelheim and Genentech
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: remdesivir, dexamethasone, and other treatments not yet approved to treat COVID-19
Update: As of October 22, 2020, remdesivir is now approved for COVID-19 infection.
Update: As of October 22, 2020, remdesivir is now approved for COVID-19 infection.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of Boehringer Ingelheim and Genentech. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katlyn Cooper at kcooper@achlcme.org
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.